Patents by Inventor Jingxuan ZHANG

Jingxuan ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250145322
    Abstract: A method of overmolding an object of interest with a protective coating is disclosed, which includes receiving a mold having a top half and a bottom half dimensioned for an object of interest, placing the object of interest into the bottom half of the mold, spreading a layer or laying a sheet of a mixture cellulose nanofibril (CNF) and carboxymethyl cellulose (CMC) on to the object of interest, placing the top half of the mold onto the CNF/CMC layer, applying a predetermined pressure between the top and bottom halves of the mold, applying a predetermined amount of heat to the mold, to thereby molding the CNF/CMC mixture onto the object of interest, and removing the object of interest with the layer of CNF/CMC formed thereon from the mold after a predetermined amount of time.
    Type: Application
    Filed: February 15, 2023
    Publication date: May 8, 2025
    Applicant: Purdue Research Foundation
    Inventors: Jeffrey YOUNGBLOOD, Jingxuan ZHANG, Endrina FORTI
  • Patent number: 12077602
    Abstract: IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin ?4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: September 3, 2024
    Assignee: Beijing SIG Biopharmaceutical Technology Co., Ltd.
    Inventors: Xiaoyan Qiu, Jingshu Tang, Zhi Yang, Chong Wang, Jingxuan Zhang, Hua Zhu, Zihan Geng, Yang Liu, Wenhua Jiang, Jing Huang
  • Publication number: 20200369785
    Abstract: IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin ?4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.
    Type: Application
    Filed: August 8, 2018
    Publication date: November 26, 2020
    Applicant: Beijing SIG Biopharmaceutical Technology Co., Ltd.
    Inventors: Xiaoyan QIU, Jingshu TANG, Zhi YANG, Chong WANG, Jingxuan ZHANG, Hua ZHU, Zihan GENG, Yang LIU, Wenhua JIANG, Jing HUANG